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Non-Hodgkin lymphomas (NHLs) account for 4% of all malignancies. 5-year survival rate increased to 50% with new
treatment modalities, however there is need for new effective treatment for the more aggressive, relapsing forms.
Recently, CTLA4-FasL, that can bind to B7 and Fas receptor (Fas), was shown to induce robust apoptosis of cell lines
originating from B cell lymphomas expressing both B7 and Fas, by activating pro-apoptotic signals in parallel to
abrogating anti-apoptotic ones. The present study focuses on the unique properties of CTLA4-FasL as a potent
apoptosis inducer of malignant cells in-vitro and in a xenograft model. CTLA4-FasL was found to naturally form a
stable homo-hexamer. CTLA4-FasL induces robust apoptosis of a large variety of malignant cells while relatively
sparing non-malignant ones, being more efficient when both receptors (B7 and Fas) are expressed on target cells.
Even in non-B7 expressing cells, CTLA4-FasL exhibited better apoptotic activity than its parts, alone or in combination,
however, only in B7 expressing cells apoptosis occurs at low concentrations and CTLA4-FasL induces activation of
apoptotic signals and reduces anti-apoptotic ones. Importantly, CTLA4-FasL efficiently inhibited the growth of human
B cell lineage tumors in a xenograft model, by provoking tumor cells’ apoptosis. Thus, CTLA4-FasL, a natural
homo-hexamer protein, induces robust apoptosis of malignant cells, in-vitro and in-vivo. In B-cell lymphoma,
its potency stems from the combination of its synergistic effect of activating the caspases while abrogating
the anti-apoptotic signaling, with its unique hexameric structure, making CTLA4-FasL a promising candidate
for aggressive B cell lymphomas treatment.Introduction
Non-Hodgkin lymphomas (NHLs), as a disease set, is
among the ten most malignant tumors, accounting for
approximately 4% of all malignancies in both men and
women [1]. NHLs are of B or T-lymphocytes lineage
with most (80-90%) of them being of B-cell origin [2,3].
Though prognosis and treatment depend on specific
type and stage, irradiation and chemotherapy have been
proven effective in many NHL patients. New protein-
based therapeutics, such as anti-CD20, have been re-
cently added to the treatment toolbox [4]. The overall
5-year survival rate has increased to approximately 50%,
but there is still need for new effective treatment for the
more aggressive and relapsing forms of the disease [5].
Activated B-cells are known to express high levels of B7
receptors, also known as CD80 (B7.1) and CD86 (B7.2),* Correspondence: michale@hadassah.org.il
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unless otherwise stated.which are required for T-cell activation as part of a co-
stimulatory signal between the T-cell CD28 receptor and
the B7 receptors on antigen-presenting cells including B
lymphocytes [6]. Similarly to activated B-lymphocytes,
B-cell lymphoma cells also express high levels of B7 mol-
ecules [7]. CTLA4 (Cytotoxic T-Lymphocyte Antigen 4),
also known as CD152, is a Type-I membrane protein that
down-regulates the immune response. CTLA4 is similar to
CD28 in that they both bind to B7, however, whereas CD28
transmits a positive T-cell activation stimulatory signal,
CTLA-4 does not. The membrane-bound CTLA-4 is
known to function as a homodimer, interconnected by a
disulfide bond [6]. CTLA4’s strong binding affinity to B7
led to the design of protein-based therapeutics, linking the
CTLA4 extracellular domain to an antidody Fc domain
(CTLA4-Fc), that is already approved for use in auto-
immune diseases and transplantation [8]. In these chimeric
constructs, both the CTLA4 and the Fc domains form a
natural homo-dimer [8]. FasL is a Type-II membraneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(Fas), resulting in cellular apoptosis [9,10]. FasL and Fas
belong to the tumor necrosis factor (TNF) family. FasL:Fas
interactions play a cardinal role in immune response modu-
lation, as well as tumor growth and progression [11]. FasL,
like other TNF super-family members, functions as a
homo-trimer that binds to and signals through a trimerized
Fas [12,13]. Upon FasL trimer binding and trimerization of
Fas, a death-inducing signaling complex (DISC) is formed
within the target cell, followed by activation of the caspases
cascade and subsequent apoptosis [14]. Importantly, studies
have shown that two adjacent trimeric FasL are required
for optimal Fas signaling and the formation of DISC [15].
Also, hexameric recombinant form of FasL, termed as
MegaFasL, was shown to induce robust, caspase-dependent
apoptosis in Fas bearing cells [16,17]. Morover, hex-
americ FasL was found to recruit more Fas into lipid
rafts than the trimeric form of FasL, in agreement with
its higher efficacy [18].
Signal-Converting-Proteins (SCP) are a novel type of
bi-functional fusion proteins that are formed by directly
linking an extracellular domain of a type I membrane
protein (extracellular amino-terminus), to the extracellu-
lar domain of a type II membrane protein (extracellular
carboxyl-terminus), creating a fusion protein with two
active sides. CTLA4-FasL is one such SCP, in which the
N-terminal side is the extracellular domain of CTLA-4
and the C-terminal side is composed of the extracellular
domain of Fas-ligand (FasL) [19]. Since CTLA4-FasL has
the ability to bind to B7 molecules and to Fas, and in
doing so, concurrently, to inhibit co-stimulation andFigure 1 CTLA4-FasL molecular structure. (A) SDS-PAGE analysis of the
(B) Western blot analysis using anti CTLA4 antibody following enzymatic re
Focusing analysis of CTLA4-FasL at pH3-7 and pH3-10.induce apoptosis. CTLA4-FasL has been shown to
efficiently induce apoptosis of activated T-cells [20] and
to function as a strong immunomodulator in multiple
autoimmune and transplantation animal models [21].
Recently, we have shown that CTLA4-FasL can induce
robust apoptosis of B cell lymphoma cell lines by activat-
ing pro-apoptotic signals in parallel to abrogating anti-
apoptotic ones [22].
The first study describing CTLA4-FasL identified it as
a homo-trimer, but since CTLA4 naturally forms a
homo-dimer, while FasL naturally forms a homo-trimer,
the authors raised the possibility that CTLA4-FasL can
form a homo-hexamer on the surface of the target cell
when anchored to the B7 molecules through the CTLA4
moiety [19]. In the present study, we present data sug-
gesting that CTLA4-FasL naturally forms a stable and
soluble homo-hexamer and propose a unique mode-of-
action model for the treatment of B cell lymphoma. We
also demonstrate that CTLA4-FasL confers a specific and
highly effective killing of tumor cells of the B cell lineage,
both in-vitro and in-vivo, indicating that CTLA4-FasL
might have a possible role as a new anti-cancer agent.
Results
CTLA4-FasL purification
To start, we looked at the purified CTLA4-FasL using
SDS-PAGE. Although the predicted molecular weight
of CTLA4-FasL is approximately 31kD, the fusion
protein migrates in reduced conditions as a protein of
approximately 43kD (Figure 1A). Treating the produc-
tion media samples with the “Peptide N-Glycosidase F”CTLA4-FasL under reducing conditions, coomassie G-250 stain.
moval of the N-glycan chains from the protein. (C) Iso-Electric
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resulted in a shift in molecular weight (MW) from ~45 kDa
to ~33 kDa (Figure 1B), indicating that the apparent
difference in MW is due to protein glycosylation. In
addition, by using Iso-Electric-Focusing analysis, we found
that the actual iso-electric point (pI) of CTLA4-FasL is
approximately 4.7-5.2, while its theoretical pI is 6.59,
supporting the notion that CTLA4-FasL is glycosylated
(Figure 1C).
As mentioned in the material and methods section, util-
izing the glycosylation of CTLA4-FasL, a preliminary puri-
fication process was developed, in which Concanavalin-A
(Con-A) chromatography was used as the main capture
step. This was followed by two successive size-exclusion
chromatography (SEC), yielding CTLA4-FasL at over 90%
purity as measured by SDS-PAGE (Figure 1A).Figure 2 Higher order structure of the CTLA4-FasL. (A) Gel filtration chrom
in the table below. (B) Analytical SEC-HPLC. The retention times of the reference
(D) SEC-HPLC analysis of the concentrated CHO-S cells harvest (left panel, black
Gyrolab analysis of CTLA4-FasL content in the fractions (right panel, red dots, asCTLA4-FasL forms a hexamer
To further study the higher-order structure of CTLA4-
FasL, purified CTLA4-FasL was initially analyzed by
gel-filtration chromatography. The protein peak of CTLA4-
FasL fractionated at a volume similar to that of Catalase,
with MW of 232kD; indicating that most of the CTLA4-
FasL protein migrates as a peak of approximately 250kD
(Figure 2A). Since this observed product size of about
250kD was significantly larger than the predicted homo-
trimer suggested previously (e.g., ~130kD) [19], analytical
Size-Exclusion High-performance Liquid Chromatography
(SE-HPLC) and native-PAGE were used to study the
actual product size at higher resolution. Surprisingly,
by using SE-HPLC we found that roughly 90% of the
fusion protein migrates as a peak of approximately
250kD, which is consistent with the size of a homo-atography. The retention volumes of the reference proteins are presented
proteins are presented in the lower panel. (C) Native-PAGE analysis.
, as compared to the purified CTLA4-FasL profile, blue), followed by a
compared to the purified CTLA4-FasL profile, green dots).
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found mostly as a higher-molecular-weight (HMW)
peak (Figure 2B). When the samples were analyzed by
Native-PAGE, an identical pattern was found (Figure 2C),
with most of the protein migrating as a 250kD band
and a minor band of approximately twice that size,
i.e., 500kD.
To test if the CTLA4-FasL homo-hexamer structure is
formed only after purification, at the highly concentrated
preparations of the protein, a similar SE-HPLC analysis
was performed on harvested production media, before
any purification was carried out, and the amount of
CTLA4-FasL in the SE-HPLC fractions was quantified
by CTLA4-FasL Gyrolab analysis. As can be seen in
Figure 2D, most of the CTLA4-FasL in the harvest
media (based on Gyrolab analysis) corresponds to a large
SE-HPLC peak with retention-time identical to that of
the CTLA4-FasL homo-hexamer, suggesting that the vast
majority of the CTLA4-FasL fusion protein is in the form
of a homo-hexamer structure already at the concentrated
harvest media, before any purification took place.CTLA4-FasL induced apoptosis is correlated with relevant
receptors expression patterns on target cells
The unique structure of the CTLA4-FasL chimera,
predicts Fas-related apoptotic activity coupled to B7
targeting. To assess if these indeed is the case, we first
measured the in-vitro killing activity of purified CTLA4-
FasL on 13 different malignant and non-malignant
human cell-lines. CTLA4-FasL was found to induce a
significant, dose dependent killing effect in seven out
of the ten cancer cell-lines we assessed, while it had
almost no killing effect on the three non-malignant











Human kidney cells (non-malignant)
PCS-400-010
PCS-400-011
Human lymphoma (B cells)
Raji
JY
Human multiple myeloma RPMI 8226
Human leukemia HL-60
Different human cell lines were incubated with different concentrations of CTLA4-FAs predicated, enhanced CTLA4-FasL killing effect
was observed when human B cell lymphoma cancer
cell-lines were cultured in the presence of the protein
(Table 1). Of note, no viable cells of the B lineage could
be detected in cultures were CTLA4-FasL was added at
30 ng/ml and above whereas in other, B7 negative cell
lines this maximal effect of CTLA4-FasL could be seen
only at concentrations above 300 ng/ml or not at all
(Additional file 1: Figure S1 and not shown). This is of
particular importance since these B-cells are known to
express B7 receptors, suggesting a correlation between
activity and specific receptor expression. To study this
hypothesis, we used FACS analysis to quantify the ex-
pression of the three target receptors of CTLA4-FasL,
namely CD80 (B7.1), CD86 (B7.2) and CD95 (Fas), on
the different human cancer cell lines. As can be seen in
Figure 3, the APL HL60 Human Leukemia cell line,
found to be CTLA4-FasL resistant by the bioassay, ex-
presses very low levels of surface CD86 and undetectable
CD80 and Fas levels. Similarly, the multiple myeloma
cell line, RPMI8226 also found to be CTLA4-FasL resist-
ant, expresses only low surface levels of Fas and CD86,
with no CD80. In contrast, the JY and Raji B cell lymph-
oma cell lines, shown to be highly sensitive to CTLA4-
FasL, express high levels of CD80, CD86 and CD95
(Figure 3 and Additional file 1: Figure S1B). Cell lines
expressing only Fas (A498 and SK-HEP1) were moder-
ately sensitive to CTLA4-FasL. These findings suggest
that cells expressing both receptors are highly sensitive
to CTLA4-FasL, cells expressing just Fas, are moderately
sensitive, while cells that express none of the receptors or
just B7 are resistant to CTLA4-FasL’s effect. Importantly,
we previously tested another fusion protein, CD40-FasL,
that cannot bind to B7 molecules [22]. CD40-FasL was
much less potent in inducing apoptosis of the B cell lineagefferent malignant and non-malignant human cell-lines
Killing effect ~EC50 Incubation time
Positive 1.0 nM 24 hours
Positive 1.5 nM 24 hours
Negative >>120 nM 48 hours
Negative 100 nM 24 hours
Positive 1.0 nM 24 hours
Positive 2.0 nM 24 hours
Positive 1.0 nM 24 hours
Negative 100 nM 24 hours
Negative 100 nM 24 hours
Positive 0.02 nM 24 hours
Positive 0.04 nM 24 hours
Negative >120 nM 24 hours
Negative >>120 nM 24 hours
asL for 24 or 48 h. Cell viability was tested using the MTS assay.
Figure 3 Receptors expression on different human cell lines. The protein expression level of B7-1 (CD80), B7-2 (CD86), and Fas (CD95) was
determined by immunostaining of cells with the corresponding antibodies, followed by flow cytometeric analysis. The results represent the
average of at least two independent experiments +/- SD.
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FasL, but was extremely effecting in causing apoptosis
of CD40L and Fas expressing cells. As we now find that
CTLA4-FasL is a hexamer, we performed a gel filtration
of the CD40-FasL conditioned medium to test whether
it is also a natural hexamer. Gel filtration fractions were
loaded on SDS-PAGE and subjected to Western blot
analysis using anti FasL Ab (Additional file 2: Figure
S2B) or analyzed by CD40 ELISA (Additional file 2:
Figure S2C). CD40-FasL was found mainly in fractions
corresponding to ~ 300 – 500 kDa indicating a hex-
americ structure. As both proteins are hexamers, the
fact that CD40-FasL is extremely effective in inducing
apoptosis in CD40L and Fas expressing cells [22], but
has much lower activity on B7 and Fas expressing cells
when compared to CTLA4-FasL, supports the importance
of the CTLA4 binding to the B7 molecules for inducing
the robust apoptotic effect of CTLA4-FasL on B7
expressing cells.CTLA4-FasL apoptosis-based effect is greater when
compared to its two subunits or their combination
We have shown in the past that his6-CTLA4-FasL
induces efficient apoptosis of lymphatic cancer cells by
utilizing a dual signaling pathway that includes Fas-
mediated apoptosis of CD95 expressing cells, coupled to
the abrogation of cFLIP expression in cells that express
B7 as well [22]. Also, we have previously shown that
CTLA4-FasL inhibitory effect on T lymphocytes activa-
tion is mediated by apoptosis induction, through the
caspases cascade [20]. To further investigate CTLA4-
FasL mode-of-action in cancer cell line, we studied if
CTLA4-FasL cytotoxic effect can be abrogated by the
pan-caspase inhibitor (Z-VAD), caspase 8 inhibitor (Z-
IETD-FMK) and caspase 9 inhibitor (Z-LEHD-FMK) on
malignant cell lines positive for Fas only. As can be seen
in Figure 4A, the pan caspase-inhibitor resulted in full
inhibition of CTLA4-FasL killing effect of the Sk-Hep1
and A498 cell lines. The inhibitors of caspase 8 and 9
Figure 4 (See legend on next page.)
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Figure 4 CTLA4-FasL effect on pro and anti apoptotic signals. (A) Sk-Hep1 (left) and A498 (right) cell lines were pre-incubated with or without
caspase inhibitors (Z-VAD-FMK (general), Z-LEHD-FMK (caspase 9), Z-IETD-FMK (caspase 8)) for 1 hour followed by incubation with his6CTLA4-FasL at
different concentrations for 24 hours. Cells’ viability was tested by the MTS assay. The results represent the average of three independent experiments. +/-
SE (*p≤ 0.05). (B) Sk-Hep1 cells were incubated with CTLA4-FasL, sFasL, CTLA4-Ig or combination of the later two for 24 hours. Cell viability was tested by
the MTS assay. The results represent the average of four independent experiments. +/- SE (*p≤ 0.05). (C) CTLA4-FasL effects on the expression of apoptotic
and anti-apoptotic proteins in B cell lymphoma cell lines (left) and RCC (right). Raji and A498 cell lines were incubated with indicated concentrations of
CTLA4-FasL, sFasL, CTLA4-Ig or the combination of the later two for 2 h. Whole cell lysates were analyzed by Western blot. These are representative results
of the three independent experiments. (D) Effect of B7 blockade on CTLA-FasL’s effect on pro and anti apoptotic signals – Raji cell lines were incubated
for 1 h with 1 μg/ml of anti CD80, anti CD86 or both prior to the addition of CTLA4-FasL (50 ng/ml). Cells were collected after 2 h. Whole cell lysates were
analyzed by Western blot. (E) CTLA4-FasL effect on NFκB pathway - A498 (lower panel) and Raji (upper panel) cell lines were incubated with indicated
concentrations of CTLA4-FasL, sFasL, CTLA4-Ig or the combination of the later two for 2 h (Raji) or 6 h (A498). Whole cell lysates were
analyzed by Western blot.
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that CTLA4-FasL activity is mediated by both the intrin-
sic and the extrinsic apoptotic pathways. Of note, cas-
pase 8 inhibitor was more potent than the caspase 9
inhibitor.
SCP chimeras have been shown to confer superior
activity over their parts, separately or in combination
[19,22]. However, this was tested previously only in tar-
get cells that express binding molecules to both SCP
sides [19,22]. As the hepatocellular carcinoma (HCC)
cell lines SK-Hep1 and HEPG2, do not express B7 mole-
cules (Figure 3 and not shown), and therefore can bind
to the FasL only, we wanted to test if this superior activ-
ity will still be evident. For that, cells were incubated in
the presence or absence of soluble CTLA4 (CTLA4-Fc),
soluble FasL (FLAG-FasL) or the combination of the
latter two for 24 h, and cell viability was measured by
MTS. As seen in Figure 4B CTLA4-FasL’s cytotoxic
effect is significantly more potent than that of its
components, even when combined. Thus, CTLA4-FasL
is superior to its components even in non-B7 expressing
cells, suggesting its FasL domain is presented to the Fas
in an exceptionally effective way, probably because it is a
hexamer and not a trimer, as it was previously shown
that a hexameric FasL is more potent than a trimeric
one [15,23].
Next, we studied the effect of CTLA-FasL and its
separate parts on the FasL: Fas signaling cascades in cells
that either bear or lack B7. As can be seen in Figure 4C,
in the A498 cell line, that is devoid of B7 expression,
CTLA4-FasL induces effective propagation of the pro-
apoptotic signaling such as caspase 3, 8 and PARP cleav-
age, only at high concentrations (500 ng/ml) and does
not differ from sFasL [24]. In contrast, in Raji cells, that
do express B7, the effect of CTLA4-FasL is already
evident at 50 ng/ml and the superiority over sFasL is
apparent. In addition, at the lower concentrations, the
proapoptotic protein BID is truncated to its activated
form tBID, and caspase 9 is cleaved only in the B7-
expressing Raji cells (Figure 4C and Additional file 3:
Figure S3A-H), again stressing the advantage of CTLA4-FasL, and imply the involvement of the mitochondrial
apoptotic pathway [25,26]. Also, cFLIP-L that is known
as an anti-apoptotic protein that interferes with caspase
8 activation is cleaved to its N-terminal form p43
[27,28]. We find rapid abrogation of FLIP-L expression
at 50 ng/ml in CTLA4-FasL treated cells as opposed to
sFasL treated cells only in B7 expressing cells. Import-
antly, in the B7-positive Raji cell line, we find a signifi-
cant decrease in the expression of the anti-apoptotic
protein c-IAP2 [29,30], while no such changes was seen
in the A498 cells even at the higher concentration of
CTLA4-FasL (Figure 4C). This effect was completely
abrogated by using blocking antibodies against CD80
and CD86, stressing the importance of the binding of
the CTLA4 domain to the B7 molecules (Figure 4D).
All of these observations suggest that CTLA4-FasL is
more potent than sFasL at low concentrations in cells
expressing both B7 and Fas. Similar findings were found
with JY, another B7 expressing cell line of the B-cell
lineage (data not shown). Of note, as activation of the
Fas was shown to induce pro-proliferative signals [31],
we looked at the expression of IkappaB-α. The expres-
sion of IkappaB-α is decreased in B7 negative cells
treated with CTLA4-FasL from the concentration of
1000 ng/ml and above, and already at 50 ng/ml in B7
positive cells (Figure 4E).
CTLA4-FasL inhibits tumor growth and improves mice
survival in a B-cell lymphoma xenograft model
Prior to initiation of studies in a mouse disease model,
we measured the basic pharmacokinetic (PK) parameters
of CTLA4-FasL in mice. The protein serum levels were
quantified by a CTLA4 commercial ELISA at specific
time points following subcutaneous (sc) injections.
CTLA4-FasL levels were shown to reach the highest
values approximately 2 hours post injection with T1/2 of
approximately 4-5 hours post injection (Figure 5). Simi-
lar results were obtained in both Balb/C and NUDE
mice (not shown).
For exploring CTLA4-FasL efficacy in-vivo, NUDE
mice were injected (sc) with JY cells and followed daily
Figure 5 Pharmacokinetic analysis of CTLA4-FasL. CTLA4-FasL at different doses was injected s.c. to mice at a total volume of 150 μl per mouse. Mice
were sacrificed at various time points (0-24 h) post injection. CTLA4-FasL level in plasma was quantified by Human Soluble CTLA-4 ELISA kit.
Figure 6 CTLA4-FasL inhibits tumor growth in vivo. Ex vivo JY
cells were injected subcutaneously to irradiated NUDE mice. At day 5
after JY injection, tumor volume was calculated and mice were treated
daily with subcutaneous injections of CTLA4-FasL or PBS for 5 days.
(A) Tumor volume. Results represent the mean +/- SE volume of tumors,
(n = 10 for each group). *P < 0.05 between PBS group and 10 ug*2 or
PBS vs 25 ug*2. **P <0.01 respectively. (B) The survival curve of the
experimental groups and control.
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were treated based on the PK results, with twice-daily sc
injections of various CTLA4-FasL dosages or vehicle for
4 consecutive days. As illustrated in Figure 6, treatment
with both 50 ug and 20 ug daily dosages of CTLA4-FasL
for 4 days, significantly inhibited the growth of human
JY xenograft tumors (Figure 6A) and significantly im-
proved survival of the treated mice (Figure 6B). Since
the 20 ug/day dose was found to be as effective as the
50ug dose, we next tested the effect of lower dosages. In
a second experiment we found that five days administra-
tion of 10 ug/day significantly inhibited tumor growth,
with a significant effect lasting to ~20 days, while a low
dose treatment of 4 ug/day for 4 consecutive days, which
was repeated for 4 weeks, seems to keep tumor volumes
at a stable reduced state (Figure 7A).
In agreement with tumor volume and the survival in-
dexes, the high efficacy of CTLA4-FasL treatment of JY
xenograft tumors was further illustrated by the immuno-
staining of tumors removed from the mice, with anti-
cleaved casapase 3. As seen in Figure 7B, almost all
tumor cells in CTLA4-FasL treated mice undergo
apoptosis, while only very few tumor cells from vehicle
treated mice stained positive to anti cleaved caspase 3.
As FasL and agonistic anti-Fas Abs were previously de-
scribed to be significantly hepatotoxic [32,33], at another
experiment mice from vehicle or 100 microgram/day
CTLA4-FasL treated groups were sacrificed 8-30 days
after last injection. Representative harvested livers stained
with hematoxilin eosine are seen in Figure 7C. In
Livers harvested from mice treated with 100 μcg a day
for 4 days no significant liver damage was observed.
Of note, at higher doses, liver toxicity was evident,
Figure 7 CTLA-4•FasL inhibits tumor growth in vivo. (A) Ex vivo JY cells were injected subcutaneously to irradiated NUDE mice. At day 5 after
JY injection, tumor volume was calculated and mice were treated daily with subcutaneous injections of CTLA4-FasL (10 μg twice a day for 5 days
for one treatment course or 2 μg twice a day for 4 days for four consecutive weeks). Control animals received similar volume of PBS. The results
represent the mean +/- SE volume of tumors (n = 10 for each group). * - P <0.05, **P <0.01 between PBS group and treatment group (B) Five
days post s.c. injection of human JY tumor cells to irradiated-NUDE mice the mice were treated with 10 ug CTLA4-FasL or PBS twice a day for 5
consecutive days. Tumors were harvested one hour after last injection, fixated and embedded in paraffin, and tissue sections were processed
and stained with anti cleaved caspase 3 antibody. (C) 8 days following last CTLA4-FasL (100 μg a day, 4 days), or vehicle injection mice livers
were harvested, fixated and embedded in paraffin, and stained with H&E.
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CTLA4-FasL as dodecamers were present (not shown).
Discussion
In the present study we investigated the unique properties
of the signal converter protein CTLA4-FasL as a potent
apoptosis inducer of malignant cells. The main findings
are: 1. CTLA4-FasL naturally forms a stable homo-
hexamer; 2. CTLA4-FasL induces robust apoptosis of ma-
lignant cell lines while relatively sparing non-malignant
ones; 3. The CTLA4-FasL killing effect is more efficient
when both relevant receptors (e.g. B7 and Fas) are
expressed on target cells; 4. Even in non-B7 expressing
cells, CTLA4-FasL exhibited significantly higher apoptotic
activity than its parts, alone or in combination; 5. In B7
expressing cell CTLA4-FasL is highly efficient in activating
apoptotic signals while diminishing the anti-apoptotic ones,
and 6. CTLA4-FasL efficiently inhibited the growth of
human B cell lineage tumors in a xenograft model.
Bi-specific and multi-specific biological drugs are be-
lieved to develop into the “next generation” of protein-
based drugs. Mostly combining functional units of two
known biological targets, this drug-development field is
currently lead by bi-specific antibodies [34,35], whileother bi-specific technologies, such as Signal Converter
Proteins, are being assessed as well [20,22,36,37]. As we
have shown in this study and previous ones, the main
advantage of bi-specific biological drugs over existing
biological drugs, that comprise only one target, is a sig-
nificant synergistic effect which cannot be obtained by
simply administrating the functional activity units alone
or in combination [22]. These synergistic effects have
been mainly suggested to stem from the ability of bi-
functional molecules to influence two or more biological
pathways concomitantly [38]. Notably, the efficient
apoptotic activity induced by CTLA4-FasL is highly spe-
cific for human B cell lymphoma cells that express both
a functional Fas receptor and B7 receptors, supporting
the notion that more than one biological signaling
pathway are involved. Indeed, in B7 expressing cells,
CTLA4-FasL provoked activation of the caspases cas-
cade and abrogated anti-apoptotic signals at very low
concentrations, a phenomena that could not be mim-
icked by CTLA4-Fc, sFasL or their combination. Most
interestingly, abolishment of the c-IAP2 protein expres-
sion was seen only when B7-expressing cells were incu-
bated with CTLA4-FasL and not with sFasL, even when
the later was used at much higher concentrations,
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responsible for the effect observed, and that the CTLA4:
B7 interaction of the fusion protein might play a se-
parate significant role. Of note, cIAP and RIP have been
implicated before as responsible for some tumors’ resist-
ance to FasL or TRAIL mediated apoptosis [39,40], and
c-IAP antagonists have been shown to sensitize cancer
cells to TRAIL-induced apoptosis [41]. Significantly, in
B7 negative cells this dual effect of CTLA4-FasL could
not be elicited, though at higher concentration of
CTLA4-FasL, effective activation of the casapses was
observed. Importantly, this also suggests that measuring
the expression of Fas, CD80 and CD86 in patient tumor
samples may be used as a biomarker for patient that
might benefit from this treatment.
Intriguingly, CTLA4-FasL potency was higher than
that of trimeric FasL, CTLA4-Fc or their combination
even when incubated with non-B7 expressing cells, mak-
ing other explanations for its robust potency plausible.
In this study we present data suggesting that a hexame-
ric, higher-order CTLA4-FasL structures may play a
significant role in the activity and potency of these novel
bi-specific drugs, as has been shown for FasL [15,23].
As reported for other TNF-super family members, ac-
tivation of the Fas apoptosis pathway requires trimeriza-
tion of Fas receptors upon binding of FasL trimers [12].
Moreover, it was previously shown that efficient Fas acti-
vation requires two adjacent such trimerization events
[15] and that hexameric forms of FasL are highly effect-
ive in apoptosis induction [19]. Therefore, the finding
that the natural stochiometry of soluble CTLA4-FasL is
a homo-hexamer is of great significance for understand-
ing its unique, robust apoptotic capabilities. Being a
hexamer, CTLA4-FasL is capable of presenting two
functional trimers of FasL to their relevant receptors,
resulting in optimal initiation of the apoptosis signaling
pathway to the malignant cells.
The formation of a membrane bound CTLA4-FasL
homo-hexamer was suggested previously [19]. Since onlyFigure 8 Schematic model of the CTLA4-FasL homo-hexamer. Monom
the FasL. Trimer is composed of the FasL trimer and three domains of the
CTLA4-FasL trimers may form a homo-hexamer, made of dimer of trimmer
dodecamer state.homo-trimers were identified at that earlier study, the
authors suggested that two CTLA4-FasL trimers may
form a homo-hexamer on target cell’s surface when an-
chored to B7 molecules, thereby inducing an extremely
efficient apoptotic effect that would explain the high
efficacy of CTLA4-FasL observed in that report. Here
we present data suggesting that CTLA4-FasL naturally
form a soluble and stable homo-hexamer as early as it is
produced and that this structure maintains its stability
through a purification process that includes harsh condi-
tions and multiple freeze/though cycles (not shown).
The stable hexameric structure can be explained by
the fact that CTLA4 naturally forms a disulfide-linked
dimer, while FasL naturally forms a stable trimer, thus,
as suggested in Figure 8, a CTLA4-FasL trimer would
possess an “open cysteine” that could link one such tri-
mer to a second trimer, forming a stable CTLA4-FasL
homo-hexamer.
Using a xenograft human-mouse disease model we
show that CTLA4-FasL has the ability to inhibit the
growth of tumors originating from B lymphocytes
lineage, and to provide a significant beneficial effect on
mice survival, in a dose dependent manner and at very
low dosages. We show that this in-vivo effect is mediated
by activation of the caspases cascade, as can be seen by
the increased cleaved caspase 3 in immunohistichemistry
of the tumors.
Conclusions
In summary, in this study we present data that the fusion
protein, CTLA4-FasL induces effective apoptosis of B lym-
phoblastoid cells, in-vitro and in-vivo, in a highly efficient
way. Also, in the case of B7 expressing cells, its potency
stems from the combination of its synergistic effect of
activating the caspases cascade while abrogating the anti-
apoptotic signaling, with its unique natural hexameric
structure. We believe that this combination of properties,
make CTLA4-FasL an extremely potent apoptosis inducer
of B7 expressing tumors, such as B cell lymphomas.er represents one domain of the CTLA-4 connected to one domain of
CTLA-4, while two of them are connected by a disulfige bridge. Two
s or trimer of dimers, resulting in a shift towards a small fraction of a
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Protein production and purification
The DNA encoding for CTLA4-FasL was synthesized at
GENEART (Germany) based on the amino-acid sequence
indicated in Figure 9A, and cloned into a UCOE expression
vector (Cobra Biologics, Figure 9B).
CHO-S cells (Life technologies GIBCO, Invitrogen
Corporation, NY, USA) were grown in CD-CHO medium
(Life technologies) and transfected with 30 micrograms
linearised DNA using DMRIE-C (Life technologies). Puro-
mycin (Invitrogen) at 12.5 micrograms/ml was used for
selection. CTLA4-FasL in culture media was quantified by
a commercial FasL ELISA kit (e-Bioscience, CA, USA).
Clones with the highest expression were expanded. One
clone, with highest level of expression, was selected for
limiting dilution, after which a final clone was selected
based on growth profile analysis and CTLA4-FasL expres-
sion levels, tested by ELISA.
The selected clone was inoculated into a 50 L single
use bioreactor. Cultivation and fed batch process
medium was 50% CD CHO (Invitrogen), 50% EX-CELL®
CHO 5 (SAFC, SIGMA-ALDRICH), supplemented with
8 mM Glutamax and 1× HT (Hypoxathine 0.1 mM,
Thymidine 0.016 mM) (Invitrogen). The titer of CTLA4-
FasL at time of harvest was 50 mg/L (Gyrolab platform
immunoassay; see below).
To purify the protein, thawed production harvest was
centrifuged at 5000 g, followed by 0.2 μm filtration (10 kDa
cut-off cellulose centrifugal filters) (Sartorius-Stedim,
Goettingen, Germany) and loaded onto a Concavalin-AFigure 9 CTLA4-FasL amino-acid sequence. (A) The amino-acid sequenc
peptide of the human Urokinase protein, utilized to secrete the protein ou
expression plasmid vector.(Con-A) HiTrap column (GE Healthcare, Little Chalfont,
UK) at 7 mg/mL resin. The Con-A eluate loaded onto a
Size-Exclusion-Chromatography (SEC) Sephacryl S-200
column (GE Healthcare). The SEC eluate was 0.2 μm
filtered (Minisart syringe filter) (Sartorius-Stedim) and
frozen at -70°C.His6-tagged protein
Some of the in-vitro experiments were performed with a
His6 tagged version of CTLA4-FasL [42]. The activity of
the tagged His6CTLA4-FasL was compared to that of
the purified non-tagged CTLA4-FasL and found to be
identical (not shown).Cell lines
Liver adenocarcinoma Sk-Hep1 cell line [43], A498 Renal
Carcinoma Cell line [44] and Raji B cell lymphoma cell line
[45] were purchased from ATCC (Manassas, Virginia,
USA). The JY lymphoblastoid cell line [22] was a kind gift
from Prof. M.L. Tykocinski laboratory, Jefferson Medical
School, PA, USA. Other cell lines were a kind gift from the
Gene Therapy institute and Hepatology Unit, Hadassah
Hebrew University Medical Center in Jerusalem, Israel.
Attached cells were grown in DMEM (Gibco) supple-
mented with 10% FBS, 2 mM glutamine, 100 IU/mL peni-
cillin and 100 μg/mL streptomycin, and were detached
using Trypsin-EDTA solution. Suspended cells were grown
in RPMI (Gibco) with the same additives. All cell lines
were cultured at 37°C, 6% CO2, and tested periodically fore of the CTLA4-FasL. The underlined sequence represents the signal
t of the cell. (B) A schematic map of the CTLA4-FasL cloned in UCOE
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test kit (Biological Industries, Israel).Activity bioassay
For in-vitro examination of the CTLA4-FasL cytotoxic
effect on different human cell lines, 32,000 cells per well
(suspended cultures) or 8000 cells per well (attached
cells) in 50 ul of complete RPMI (suspended cultures) or
DMEM (attached cells) medium without Phenol Red,
were seeded in triplicates, in a flat 96-wells plate (Nunc
or similar), and 50 ul of CTLA-4-FasL (or his6CTLA-4-
FasL) dilutions (in growth media; 3000 ng/ml-0.1 ng/ml,
triplicates), or dilution media as negative control were
added. Calibration curve wells contained serial dilution
from 64,000 to 2000 cells per well for suspended cul-
tures or 16,000 to-2000 cells for attached cells in tripli-
cates. Plates were incubated for 24 hours at 37°C in 6%
CO2 humidified incubator. Cell viability was quantified
by a MTS kit (Promega, CellTiter 96® Aqueous Non-
Radioactive Cell Proliferation Assay) according to manu-
facturer instructions.SDS-PAGE, western blot and native-PAGE analysis
For CTLA4-FasL and CD40-FasL SDS-PAGE and western
blots, 4-12% Bis-Tris gel (1 mm, 12 wells, NP0322BOX,
Life Technologies) and “See Blue Plus 2” MW markers
(LC5925, Life Technologies) were used. After blocking
(skim milk) membranes (PVDF) were incubated with either
goat anti-human CTLA4 antibody (AF-386-PB, R&D
Systems, 1:300 dilution) or goat anti-human Fas Ligand
(AB126, R&D Systems, 1:100 dilution). The secondary
antibody was a donkey anti-Sheep/Goat Immunoglobulins
(HRP, AP360, The Binding Site, 1:10,000 dilution), detected
by HRP substrate 3,3′, 5,5′ – Tetramethylbenzidine (TMB,
Liquid Substrate System for Membranes, Sigma-Aldrich,
MO, USA).
For western blot analysis of intracellular proteins,
whole cell lysate were separated on 12% SDS-PAGE and
blotted according to standard procedures. Membranes
were incubated with the following primary antibodies:
anti Caspase-3, Caspase-8, Caspase-9, PARP, Bcl-2, c-
IAP-1, c-IAP2, RIP all from Cell Signaling Technology,
Danvers, MA, USA; anti XIAP (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA); anti FLIP (Enzo, CA, USA);
anti BID, anti GAPDH (Millipore, Billerica, MA, USA);
anti IkB-α (R&D). Secondary detection was performed
with HRP-conjugated antibodies (BioRad, Hercules, CA,
USA). In some experiments blocking anti CD80 and/or
CD86 Abs (MAB140 and MAB141 respectively, R&D,
USA) were added to the culture.
Native-PAGE analysis was performed with NativePAGE™
Novex® 4-16% Bis-Tris Gel (Invitrogen), according to the
manufacturer protocol. Samples were prepared with andwithout G-250 sample additive. 10uL of the CTLA4-FasL
sample and of the NativeMark were loaded to each gel lane.
Coomassie G-250 (Invitrogen) was added to the cathode
buffer and to the samples, resulting in staining of the pro-
teins during gel electrophoresis.
Gyrolab
To efficiently quantify CTLA4-FasL, a Gyrolab plat-
form immunoassay (Gyrolab Workstation, Gyros, Uppsala,
Sweden) was developed. An anti-Human CTLA-4 poly-
clonal goat antibody (AF-386 PB, R&D systems) was
selected as capture antibody, and was biotinylated using
EZ-link Sulfo-NHS-LC-Biotin (PIERCE, Thermo Fisher
Scientific Inc, IL, USA) according to manufactures proto-
col. An anti-Human Fas Ligand monoclonal mouse IgG2B
antibody (MAB-126, R&D Systems) was selected as detec-
tion antibody and was Alexa labeled using the Alexa Fluor™
647 Monoclonal Antibody Labelling Kit (Molecular probes,
Life technologies) according to manufacture's protocol.
CTLA4-FasL sample and standards were diluted into
the range 0.1 – 100 μg/ml using Rexxip CSS (Gyros,
Sweden) before being applied onto a CD Bioaffy 20
HC microlaboratory disc (Gyros). CTLA4-FasL sample
(20 nl) were transferred by centrifugal force through
minute columns (15 ml) packed with Streptavidin beads
to which biotinylated anti-CTLA4 antibodies were at-
tached. Detection of CTLA4-FasL bound to the column
was performed after addition of Alexa labelled anti-FasL
antibodies by laser induced fluorescence. Quantitation
was performed relative to a 5 parameter logistic standard
curve.
CD40-FasL – production and ELISA
CD40-FasL was produced as described before [46]. For
quantification CD40 Human ELISA Kit (Abcam, UK)
was used according to manufacturer’s instructions.
FACS analysis
1 × 106 cells were washed with PBS and re-suspended in
95 μl of staining buffer (1% BSA, 0.1% azide in PBS) and
5 μl of human Fc blocker (e-Bioscience), and incubated
on ice for 5′. Cells were immunostained with PE-anti
hCD95 (eBioscience), APC-anti hCD86 (BD) or FITC-
anti hCD80 (BD) or matching isotype Abs (PE-mouse
IgG1 kappa, APC-mouse IgG1 kappa or FITC-mouse
IgG1 kappa, respectively, all from eBioscience) on ice for
30′ and 20,000 events per sample were counted using a
BD™ LSR II Flow Cytometer, and data were analyzed
using CellQuest software (Becton Dickinson).
Size-exclusion - HPLC
Analytical size-exclusion (SE) was performed using a
Dionex HPLC instrument (Pump P580, Auto sampler
ASI-100/ASI-100 T Injector, UV/VIS Detector UVD340U,
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TSK-Gel G3000SWXL 7.8×300 mm column. Phosphate
Buffered Saline (PBS) was used as the mobile phase and
samples of <50 μg or 100 μg were injected.
Reference standards and 25% Gel Filtration Standard
(GFS, BioRad) were run before and after the samples.
The separation was performed using an isocratic separ-
ation method with a runtime of 20 min and a flow rate
of 1 ml/min. The column oven was set at 25°C and the
sample holder at 8°C. The size distribution profiles were
recorded using UV absorption at 214 nm.
Iso Electric Focusing (IEF)
CTLA4-FasL was separated on IEF gels (Novex, Life
technologies, NY, USA), at pH3-7 and pH3-10, accord-
ing to manufacturer instructions.
Gel filtration chromatography
Protein (1 mg/ml; 400 ul) was applied to a Superdex 75
analytical column (30 × 1 cm; GE-Healthcare) using AKTA
Explorer (GE-Healthcare) and eluted at a flow rate of
0.8 ml/min in buffer PBS monitoring absorbance at 280,
260 and 220 nm. Molecular weight standards catalase
(232 kDa), aldolase (163 kDa), BSA (67 kDa), OvoAlbumin
(44 kDa), Chymotrypsinogen A (25 kDa) and RNaseA
(13.7 kDa) (GE-Healthcare) were used. For CD40-FasL
containing medium the molecular weight standards are as
presented in Additional file 2: Figure S2A.
Xenograft lymphoma model
Athymic-NUDE female mice (Harlan, Israel), 4-6 weeks
of age, were maintained under defined flora conditions
at the Hebrew University Pathogen-Free Animal Facility.
All experiments were approved by the Animal Care
Committee of the Hebrew University. The JY cells used
in this study were harvested from subcutaneous JY xeno-
graft tumor, and expanded in culture. Mice were irradi-
ated (300R), and two days later JY cells in exponential
growth were harvested, washed with PBS, and injected
subcutaneously (7-10 × 106/mouse) into the right flanks
of mice. Treatment was started to each mouse individu-
ally when tumor was palpable and could be measured,
between day 4 to 7 after cells injection (most of the
animals were treated from day 5).
Mice were treated for 4 days with two 100 μl subcuta-
neous injections per day of CTLA4-FasL or the vehicle
buffer (PBS). Tumor size was measured by a micro
caliber and volume was calculated by the equation:
(w2*length/2). Mice bearing tumor of >1000 mm3 or nec-
rotic tumors were sacrificed. In some experiments, and to
further assess CTLA4-FasL effect on JY-derived tumors,
mice were sacrificed one hour post the 1st injection, at the
4th injection day (20 μg CTLA4-FasL per day). For livers
histology examination animals treated with vehicle orCTLA4-FasL (100 mcg/day, 4 days) were sacrificed 8-30
days after the last injection, and livers harvested and fixated
in 4% formaldehyde, routinely processed, and embedded
in paraffin. Transverse sections (5 μm) were stained with
hematoxylin and eosin (H&E).
Pharmacokinetics
For analysis of pharmacokinetics, CTLA4-FasL at different
doses was subcutaneously injected to mice at a total volume
of 150 μl per mouse. Mice were sacrificed at various time
points post injection. Blood was collected in heparin, kept
on ice, centrifuged at 1000 g (~3000 rpm) for 10′, plasma
was kept at -70°C. CTLA4-FasL was quantified by
LEGEND MAXTM Human Soluble CTLA-4 ELISA kit
(#437407, Biolegend, CA, USA), according to the manufac-
turer's instructions.
Immunohistochemistry
To assess CTLA4-FasL apoptosis-inducing effect in-vivo,
Athymic-NUDE mice bearing JY tumors were sacrificed
one hour post 10 ug injection, at the 5th injection day
(20 ug per day, sc, divided to two daily 10ug injections,
4 hours apart). Subcutaneous tumors were removed,
fixated in 4% formaldehyde, and embedded in paraffin.
Sections (5 μm) were deparaffinized in xylene (3×3′) and
rehydrated in graded alcohol (3×1′ 100% ethanol; 3×1′
96% ethanol). Following 5′ incubation in 3% H2O2 for en-
dogenous peroxidase inactivation, slides were incubated in
Citrate buffer (pH6; Invitrogen) and boiled in electric
pressure cooker (BioCare Medical, CA, USA) for antigen
retrieval. Samples were blocked for 30′ in CAS-BLOCK
(Invitrogen) prior to overnight incubation with the anti-
cleaved caspase 3 primary antibody (Cell Signaling #9661;
1:100 diluted in CAS-BLOCK) at 4°C in humidified box.
Following washing (3×2′ in Super Sensitive wash buffer,
BioGenex), samples were incubated for 30′ at RT with the
Simple stain MAX PO (MULTI) anti-rabbit immune-
peroxidase polymer (NICHIREI BIOSCIENCES INC.).
Diaminobenzidine (DAB; UltraVision Detection System,
Thermo scientific, MA, USA) was used as the chromo-
gen according to manufacturer's instructions, and 20''
incubation in hematoxylene (SIGMA-Aldrich) was used
as the nuclear counter-stain. Following dehydration
steps (2′ 80% ethanol, 2′ 96% ethanol, 2′ 100% ethanol,
2′ xylene) and mounting (Histomount mounting solu-
tion, Invitrogen), ×20 pictures were taken by the Nikon
ECLIPSE Ti light microscope and captured by the
DSFI-1 camera (Nikon, USA).
Additional files
Additional file 1: Figure S1. A CTLA4-FasL effects on JY – B lymphoblastic
cell line viability. 32,000 cells per well were incubated in the presence or
absence of CTLA-4-FasL (3000ng/ml-0.1ng/ml, triplicates) for 24 hours. Cell
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on Raji cells surface. Raji cells were immunostained with PE-anti hCD95,
APC-anti hCD86 or FITC-anti hCD80 or matching isotype Abs 20,000 events
per sample were counted using a BD™ LSR II Flow Cytometer. Dot plots are
presented. Data were analyzed using CellQuest software (Becton Dickinson).
Additional file 2: Figure S2. Gel filtration analysis of CD40-FasL indicating
a size compatible with a homohexamer. CD40-FasL containing media samples
were fractionized in high resolution gel filtration Superdex 200 size exclusion
chromatography. Collected fractions were analyzed by Western blot and ELISA.
A. Molecular weight standards for the gel filtration fractions. B. Western blots
of fractions 4-11 from the gel filtration of the CD40-FasL containing media
using anti-FasL Abs. C. ELISA detecting human CD40 of fractions 5-14 from
the gel filtration of the CD40-FasL containing media.
Additional file 3: Figure S3. CTLA4-FasL effects on the expression of
pro-apoptotic and anti-apoptotic proteins in B cell lymphoma (1 A-G) and
RCC (H) cell lines. Raji and A498 cell lines were incubated with indicated
concentrations of CTLA4-FasL, sFasL, CTLA4-Ig or the combination of the
later two for 2h at 37°C. Whole cell lysates were analyzed by Western
blot using the indicated Abs. Data was normalized against GAPDH by a
Quantity One program (BioRad, Version 4.6.9). Data are presented as
mean ± SE. P<0.05; CTLA4-FasL a: vs Untreated (UT), b: vs sFasL, c: vs
CTLA-4-Ig, d: vs sFasL + CTLA-4-Ig.
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